Company: JUNS
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001261
Chunk: 1501

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 6
Chunk 1501
---
Note 8) 
     -   
     -  

    Stockholders’
    Equity (Deficit): 

    Series
    A preferred stock, par value $0.0001; 5,000,000 shares authorized, nil shares issued and outstanding 
     -  
     - 
  
    Common
    stock, par value $0.0001; 125,000,000 shares authorized; 33,103,860 and 26,526,405 issued and outstanding 
     3,310  
     2,652 
  
    Additional
    paid in capital 
     30,190,827  
     17,778,498 
  
    Accumulated
    deficit 
     (26,022,129) 
     (23,582,504)
  
    Total
    stockholders’ equity (deficit) 
     4,172,008  
     (5,801,354)
  
    Total
    liabilities and stockholders’ equity (deficit) 
    $6,202,409  
    $148,592 

The
accompanying notes are an integral part of these financial statements

F-3

JUPITER
NEUROSCIENCES, INC.

STATEMENTS
OF OPERATIONS

    December
                                            31, 2024  
    December
                                            31, 2023 

    For
    the Years Ended 

    December
                                            31, 2024  
    December
                                            31, 2023 

    Expenses: 

    Research
    and development 
     492,660  
     954,793 
  
    General
    and administrative 
     2,598,622  
     2,915,978 
  
    Total
    operating expenses 
     3,091,282  
     3,870,771 

    Operating
    loss 
     (3,091,282) 
     (3,870,771)

    Other
    Income (Expenses): 

    Interest
    income 
     5,557  
     482 
  
    (Loss)
    gain on change in fair value of derivative liability 
     (53,257) 
     148,751 
  
    Interest
    expense 
     (248,366) 
     (218